Editas Medicine, Inc. (EDIT)
2.40
-0.09
(-3.61%)
USD |
NASDAQ |
Oct 23, 16:00
2.385
-0.02
(-0.62%)
After-Hours: 20:00
Editas Medicine Enterprise Value : 228.08M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 228.08M |
| October 22, 2026 | 241.90M |
| October 21, 2026 | 244.97M |
| October 20, 2026 | 255.71M |
| October 19, 2026 | 231.15M |
| October 16, 2026 | 220.40M |
| October 15, 2026 | 234.22M |
| October 14, 2026 | 208.12M |
| October 13, 2026 | 234.99M |
| October 12, 2026 | 281.81M |
| October 09, 2026 | 304.84M |
| October 08, 2026 | 295.63M |
| October 07, 2026 | 281.81M |
| October 06, 2026 | 278.74M |
| October 05, 2026 | 287.96M |
| October 02, 2026 | 261.86M |
| October 01, 2026 | 246.50M |
| September 30, 2026 | 254.18M |
| September 29, 2026 | 257.25M |
| September 28, 2026 | 244.97M |
| September 25, 2026 | 255.71M |
| September 24, 2026 | 281.81M |
| September 23, 2026 | 272.60M |
| September 22, 2026 | 307.91M |
| September 21, 2026 | 294.10M |
| Date | Value |
|---|---|
| September 18, 2026 | 274.14M |
| September 17, 2026 | 277.21M |
| September 16, 2026 | 275.67M |
| September 15, 2026 | 263.39M |
| September 14, 2026 | 280.28M |
| September 11, 2026 | 274.14M |
| September 10, 2026 | 266.46M |
| September 09, 2026 | 284.88M |
| September 08, 2026 | 324.80M |
| September 04, 2026 | 355.51M |
| September 03, 2026 | 332.48M |
| September 02, 2026 | 332.48M |
| September 01, 2026 | 330.94M |
| August 31, 2026 | 329.41M |
| August 28, 2026 | 344.76M |
| August 27, 2026 | 366.26M |
| August 26, 2026 | 347.83M |
| August 25, 2026 | 363.19M |
| August 24, 2026 | 320.20M |
| August 21, 2026 | 337.09M |
| August 20, 2026 | 310.98M |
| August 19, 2026 | 358.58M |
| August 18, 2026 | 301.77M |
| August 17, 2026 | 295.63M |
| August 14, 2026 | 292.56M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Recursion Pharmaceuticals, Inc. | 1.492B |
| Alnylam Pharmaceuticals, Inc. | 29.64B |
| Geron Corp. | 668.60M |
| Halozyme Therapeutics, Inc. | 16.24B |
| Novavax, Inc. | 1.177B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -18.23M |
| Revenue (Quarterly) | 11.89M |
| Total Expenses (Quarterly) | 30.12M |
| EPS Diluted (Quarterly) | -0.1528 |
| Gross Profit Margin (Quarterly) | 96.50% |
| Profit Margin (Quarterly) | -153.3% |
| Earnings Yield | -31.02% |
| Normalized Earnings Yield | -33.23 |